LimmaTech Starts Phase 1 Trial for S. aureus Vaccine LBT-SA7 LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 LimmaTech Biologics AG, a clinical-stage biotech company focused on developing vaccines for the prevention of life-threatening…
Breakthrough ‘Super Test’ for Prostate Cancer Developed by EDX Medical in the UK Scientists in Cambridge have unveiled a groundbreaking new diagnostic tool, hailed as a ‘super test’ for prostate cancer, with the potential to revolutionize screening, early detection, and…
European Commission Approves KOSTAIVE®, the First Self-Amplifying mRNA COVID-19 Vaccine Global biotechnology leader and self-amplifying mRNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) have announced that the European Commission (EC) has granted marketing authorization for KOSTAIVE® (ARCT-154), a breakthrough self-amplifying mRNA…
GeneDx Introduces ultraRapid Whole Genome Sequencing for NICU and PICU Patients, Offering Actionable Results in Just 48 Hours GeneDx (Nasdaq: WGS), a leading provider of genomic insights to improve health outcomes, has announced its new ultraRapid Whole Genome Sequencing, aimed…
Quantum-Si and Leading Researchers to Showcase Advances in Next-Generation Protein Sequencing™ at US HUPO 2025 Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or “the Company”), renowned as The Protein Sequencing Company™, is set to highlight groundbreaking advancements in Next-Generation Protein Sequencing™…
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath device, recently showcased its latest pre-clinical data at the 2025 Society of Interventional Oncology Annual Conference (SIO…
Latent Labs Secures $50 Million to Pioneer AI-Driven Programmable Biology Latent Labs, an emerging leader in AI-powered biological programming, has officially stepped out of stealth mode, announcing a significant $50 million in total funding to propel its innovative research and…
Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma Tivic Health Systems, Inc. (Nasdaq: TIVC) has taken a major step toward expanding its therapeutic portfolio by acquiring the exclusive worldwide license rights to Entolimod™, a late-stage…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in Molecular Pharmaceutics, highlights the platform’s unique ability to improve drug…
GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for neurodegenerative retinal diseases and…
Protein Prediction LG Develops Next-Generation AI for Protein Structure Prediction to Revolutionize Drug Discovery On February 5th, LG AI Research took a significant step in advancing the field of artificial intelligence-driven biotechnology by signing a joint research agreement with Professor…
Antibodies.com and Cactus Communications Partner to Accelerate Life Science Manuscript Publication Antibodies.com, a leading provider of high-quality biological reagents for life science researchers, has announced a strategic partnership with Cactus Communications (CACTUS), a global leader in science communication and technology.…